Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg of ethinyl estradiol and 2 mg of dienogest

被引:24
|
作者
Wiegratz, Inka
Mittmann, Katrin
Dietrich, Horst
Zimmermann, Thomas
Kuhl, Herbert
机构
[1] Goethe Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany
[2] Jenapharm GmbH & Co KG, Jena, Germany
关键词
oral contraceptives; ethinyl estradiol; dienogest; fertility regain; conception rate;
D O I
10.1016/j.fertnstert.2005.11.052
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To examine the conception rate after cessation of a combination of 30 mu g ethinyl E-2 and 2 mg dienogest (EE/DNG). Design: Prospective observational study. Setting: Population-based cohort in Germany. Patient(s): Women who wished to become pregnant after cessation of an oral contraceptive (EE/DNG). Intervention(s): None. Main Outcome Measure(s): Cumulative conception rate within 1 year after termination of EE/DNG and time to pregnancy. Result(s): After 1 year follow-up, the cumulative pregnancy rate was 86.6% (full analysis set; n = 706). When all participants with complete data were analyzed (n = 652), the cumulative pregnancy rate was 94.0%. More than 15% of the patients conceived in each of the first three cycles after termination of EE/DNG; the mean time to pregnancy was 3.5 cycles. The preceeding duration of treatment with EE/DNG did not influence the conception rate. Except in the youngest age group (16-18 years), a certain delay was observed in the other age groups. Conclusion(s): The present prospective study revealed only a slight delay in regaining fertility during the first three cycles after cessation of EE/DNG. Thereafter, the cumulative rate of conception did not differ form that observed in fertile women who attempted to become pregnant without prior conception.
引用
收藏
页码:1812 / 1819
页数:8
相关论文
共 50 条
  • [1] Modulation of ovarian function by an oral contraceptive containing 30 mu g ethinyl estradiol in combination with 2.00 mg dienogest
    Spona, J
    Feichtinger, W
    Kindermann, C
    Moore, C
    Mellinger, U
    Walter, F
    Graser, T
    CONTRACEPTION, 1997, 56 (03) : 185 - 191
  • [2] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use
    Wiegratz, Inka
    Stahlberg, Skadi
    Manthey, Torsten
    Saenger, Nicole
    Mittmann, Katrin
    Palombo-Kinne, Ernesta
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    CONTRACEPTION, 2010, 81 (01) : 57 - 61
  • [3] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters:: conventional vs. extended-cycle use
    Saenger, Nicole
    Stahlberg, Skadi
    Manthey, Torsten
    Mittmann, Katrin
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    Wiegratz, Inka
    CONTRACEPTION, 2008, 77 (06) : 420 - 425
  • [4] Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 mu g ethinyl estradiol and 2.00 mg dienogest on the hemostatic system
    Spona, J
    Feichtinger, W
    Kindermann, C
    Schneider, B
    Mellinger, U
    Walter, F
    Moore, C
    Graser, T
    CONTRACEPTION, 1997, 56 (02) : 67 - 75
  • [5] A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol
    Kluft, C
    Endrikat, J
    Mulder, SM
    Gerlinger, C
    Heithecker, R
    CONTRACEPTION, 2006, 73 (04) : 336 - 343
  • [6] Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest
    Bitzer, Johannes
    Parke, Susanne
    Roemer, Thomas
    Serrani, Marco
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2011, 3 : 127 - 132
  • [7] Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy
    Wiegratz, Inka
    Stahlberg, Skadi
    Manthey, Torsten
    Saenger, Nicole
    Mittmann, Katrin
    Lange, Evelyn
    Mellinger, Uwe
    Palombo-Kinne, Ernesta
    Kuhl, Herbert
    CONTRACEPTION, 2011, 84 (02) : 133 - 143
  • [8] Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters
    Wiegratz, Inka
    Stahlberg, Skadi
    Manthey, Torsten
    Saenger, Nicole
    Mittmann, Katrin
    Lange, Evelyn
    Mellinger, Uwe
    Kuhl, Herbert
    CONTRACEPTION, 2008, 78 (05) : 384 - 391
  • [9] Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate
    Markantes, George
    Saltamavros, Alexandros D.
    Vervita, Vasiliki
    Armeni, Anastasia K.
    Karela, Anastasia
    Adonakis, George
    Decavalas, George
    Georgopoulos, Neoklis A.
    GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (12) : 971 - 977
  • [10] Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive
    Caruso, S.
    Iraci, M.
    Cianci, S.
    Fava, V.
    Casella, E.
    Cianci, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (08) : 923 - 931